Understand the source comparison
Joint Health Peptides 2026 Update: Comparison Table
The following table compares the three primary peptides used in joint health research as of 2026, based on updated clinical trial data and dosing protocols. BPC-157 VEGF pathway upregulation, angiogenesis in peri-cartilage tissue 250mcg subcutaneous twice dail
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the three primary peptides used in joint health research as of 2026, based on updated clinical trial data and dosing protocols.
- BPC-157
- VEGF pathway upregulation, angiogenesis in peri-cartilage tissue
- 250mcg subcutaneous twice daily
- 12–16 weeks for cartilage thickness changes on MRI
- Cartilage repair, osteoarthritis, ligament healing
- Slower than expected but structurally effective. Requires patience
- TB-500
- Actin polymerisation, fibroblast migration, collagen synthesis
- 5mg subcutaneous weekly
- 3–4 weeks for symptom relief, 8–12 weeks for structural tendon repair
- Tendon injuries, ligament tears, chronic tendinopathy
- Dose-response now clarified. 5mg is the therapeutic threshold
- Type II Collagen Peptides
- Chondrocyte receptor signalling, proteoglycan and collagen gene upregulation
- 40mg oral daily
- 60–90 days for pain reduction and functional improvement
- Osteoarthritis pain, joint stiffness, cartilage support
- Works by supporting existing cartilage function. Not regeneration
- This comparison highlights that peptide selection depends on the specific joint injury or condition. BPC-157 targets structural cartilage repair over months. TB-500 accelerates tendon healing within weeks. Collagen peptides provide symptomatic relief in osteoarthritis without reversing severe cartilage loss.